CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink
CorMedix (NASDAQ: CRMD) Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving from what he described as a "single product company" to a diversified specialty pharmaceutical business focused on institutional settings of care following its 2025 acquisition of Melinta.













